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Node-negative breast cancer patients, in contrast to breast cancer
patients whose lymph nodes show tumour cell involvement at time
of primary therapy, have a low risk of suffering disease recur-
rences. About 70% of the node-negative patients are cured by
surgery alone and will therefore not need any adjuvant systemic
therapy. Nevertheless, even within this low-risk breast cancer
group, up to 30% of the patients may relapse within 10 years after
surgery and eventually die of metastasis (Clark and McGuire,
1988). Traditional histomorphological and clinical factors such as
tumour size, tumour grade, steroid hormone receptor status, age,
or menopausal status, have been used to identify the high-risk
node-negative patients who may benefit from adjuvant systemic
therapy (McGuire and Clark, 1992). However, by applying these
traditional prognostic factors, more than 75% of all node-negative
breast cancer patients will receive adjuvant systemic therapy
(McGuire and Clark, 1992), even though only about 30% of all
node-negative patients will eventually develop systemic disease.
This obvious discrepancy has stimulated the search for new prog-
nostic factors, and numerous factors have been suggested so far for
the assessment of breast cancer prognosis (Harris et al, 1992).
Tumour-biological factors such as those reflecting invasion and
metastasis or proliferation have strongly been put forward in the
literature as new prognostic markers. Several independent investi-
gations have demonstrated that the invasion markers uPA (serine
protease urokinase-type plasminogen activator) and PAI-1
(inhibitor of uPA) are statistically independent prognostic factors
to predict disease recurrence and death in node-negative breast
cancer. Elevated antigen levels of uPA and PAI-1 are associated
with poor prognosis (Duffy et al, 1990; Grøhndahl-Hansen et al,
1993; Jänicke et al, 1993; Foekens et al, 1994; Fernö et al, 1996).
Another protease, cathepsin D, has also been associated with poor
patient outcome (Rochefort, 1992).
Prior to the study of tumour-associated proteolytic factors, flow
cytometric DNA analysis was reported to yield valuable prog-
nostic information in breast cancer patients. Ploidy and, in partic-
ular, S-phase fraction have been addressed as rather powerful
prognostic factors in node-negative breast cancer (Osborne, 1989).
In recent years, immunohistochemical detection of the prolifera-
tion-associated antigen Ki-67 has also been used for proliferation
assessment. The ability to detect Ki-67 in formalin-fixed paraffin
sections by means of a monoclonal antibody, MIB1, made this
technique readily available for determination of tumour cell prolif-
eration (Dettmar et al, 1997).
Molecular markers, such as the HER-2/neu gene, which codes
for an analogue of the epidermal growth factor receptor, as well as
the tumour suppressor gene p53, have also been associated with
patient prognosis. Yet their prognostic impact is still quite contro-
versial. In addition, their unique tumour-biological role has not yet
been fully determined (Clark, 1996).
Even though there is abundant literature on so-called new prog-
nostic factors in primary breast cancer, most publications merely
compare one or two new factors to the traditional prognostic
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Correspondence to: N Harbeckfactors. In addition, subgroup analyses of clinically relevant
patient collectives such as node-negative patients are often not
performed due to small patient numbers. Therefore, after a long-
term median follow-up of more than 6 years, we have now evalu-
ated the prognostic impact of eight tumour-biological factors
(uPA, PAI-1, cathepsin D, S-phase, ploidy, Ki-67, p53, HER-
2/neu) in a homogeneous, clinically important cohort of node-
negative patients whose follow-up data were not altered by effects
of any adjuvant systemic therapy. In order to ensure comparability
of the results, we performed analysis of five factors (S-phase,
ploidy, Ki-67, HER-2/neu, p53) on adjacent paraffin sections of
the same tissue block. The prognostic impact of the tumour-
biological factors on disease-free, as well as overall, survival was
compared to that of the traditional prognostic factors tumour size,
grading and steroid hormone receptor status.
MATERIALS AND METHODS
Patients
Traditional factors (pathological tumour size, steroid hormone
receptor status, grading) and tumour-biological factors (uPA, PAI-
1, cathepsin D, S-phase, ploidy, Ki-67, p53, HER-2/neu) were
assessed in tumour tissues obtained from 125 patients with node-
negative breast cancer. Histological grade was scored according to
Elston and Ellis (1991); completely undifferentiated tumours in
which a histological subtype could not be determined were classi-
fied as G4.
Patients either had a modified radical mastectomy (n 5 83) or
underwent breast-conserving surgery with subsequent breast irra-
diation (n 5 42) at the Department of Obstetrics and Gynecology
of the Technische Universität München, Germany, between 1987
and 1991. In accordance with the standard treatment at the time,
none of the patients received any adjuvant systemic therapy.
Median age of all patients at primary therapy was 56 years (range
35–82 years). Further patient characteristics are displayed in Table
1. At time of primary therapy no patient had clinical or X-ray
evidence of distant metastases. Follow-up data was obtained every
3–6 months. Median follow-up of patients still alive at time of
analysis was 76 months (range 47–108 months). Twenty-three
patients (18.4%) relapsed. Fifteen patients (12%) died of breast
cancer and eight patients died of causes not related to breast cancer
within the follow-up period.
Methods
As described earlier (Jänicke et al, 1990, 1994a), uPA and PAI-1
have been measured in tumour tissue extracts in a prospective
fashion since 1987 for all breast cancer patients who had their
primary surgery performed at our department. uPA and PAI-1
antigen were determined by commercially available enzyme-
linked immunosorbent assays (ELISAs) in detergent extracts of
breast cancer tissue specimens and expressed as ng of antigen per
mg of tissue protein (uPA: Imubind # 894; PAI-1: Imubind # 821;
both from American Diagnostica, Greenwich, CT, USA) (Jänicke
et al, 1993, 1994a; Schmitt et al, 1997b). Levels of the protease
cathepsin D were determined in the cytosol fraction by ELSA (CIS
Bioindustries, Gif-sur-Yvette, France). Total S-phase fraction
(SPF) and ploidy were measured by flow cytometry in routinely
formalin-fixed, paraffin-embedded tissue sections processed
according to Harbeck et al (1994) and then calculated using the
computer program ModFit (Verity Software House, ME, USA)
(Dettmar et al, 1997).
Immunostaining for p53, HER-2/neu (c-erbB-2) and Ki-67
(MIB1 antibody) was performed as described (Dettmar et al, 1997;
Harbeck et al, 1998) in adjacent 4-mm-thick paraffin sections using
the alkaline phosphatase anti-alkaline phosphatase (APAAP)
method.
Statistical analysis
Correlations between continuous variables were analysed using
the Spearman rank test. Associations between continuous and/or
categorical variables were analysed using the Mann–Whitney U-
test or the c2 test as appropriate.
Determination of optimal cut-offs for dichotomized variables to
discriminate low-risk and high-risk patients was performed using
log-rank statistics. Univariate analyses for disease-free survival
were performed according to Kaplan–Meier (Kaplan and Meier,
1958; Jänicke et al, 1993) and univariate Cox analysis. Corrections
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Table 1 Node-negative breast cancer patients without adjuvant systemic
therapy. Prospective analyses were performed in all 125 patients,
retrospective analyses only in cases where sufficient tumour tissue was left
for analysis
Factors n (%)
Tumour size (cm) 125
≤2 65 (52)
. 2 and ≤ 5 56 (44.8)
. 5 4 (3.2)
Steroid hormone receptor status 125
Positive 99 (79.2)
Negative 26 (20.8)
Grading 125
G 1/2 93 (74.4)
G 3/4 32 (25.6)
PAI-1 125
Low (≤ 14 ng mg21 protein) 99 (79.2)
High (. 14 ng mg21 protein) 26 (20.8)
uPA 125
Low (≤ 3 ng mg21 protein) 83 (66.4)
High (. 3 ng mg21 protein) 42 (33.6)
Cathepsin D 121
Low (≤ 41 pmol mg21 protein) 60 (49.6)
High (. 41 pmol mg21 protein) 61 (50.4)
S-phase fraction 101
Low (≤ 6%) 55 (54.5)
High (. 6%) 46 (45.5)
Ploidy 101
Diploid (near diploid, diploid) 51 (50.5)
Aneuploid (an-, multi-, tetraploid) 50 (49.5)
MIB1 116
Low (≤ 25%) 96 (82.8)
High (. 25%) 20 (17.2)
p53 111
Negative 102 (91.9)
Positive 9 (8.1)
HER-2/neu 101
Negative 55 (54.5)
Positive 46 (45.5)to the P-values obtained in Kaplan–Meier analysis to account for
multiple testing were computed according to the procedure of
Hilsenbeck and Clark (1996).
Multivariate analyses were performed in a forward stepwise
fashion by applying the Cox proportional hazards model (Cox,
1972) using the SPSS software package (SPSS Inc., Chicago, IL,
USA) and by the CART (classification and regression trees) tech-
nique (Breiman et al, 1984; Schmitt et al, 1997b). All established
and new tumour-biological factors were included in the multi-
variate analysis. All tests were performed at a significance level of
a 5 0.05 (i.e. with a confidence interval (CI) of 95%).
RESULTS
Factors and optimized cut-off values
In 125 node-negative breast cancer patients who did not receive
any adjuvant systemic therapy, traditional histomorphological
prognostic factors, as well as invasion markers uPA and PAI-1,
were prospectively determined. Additional tumour-biological
factors (cathepsin D, S-phase fraction, ploidy, Ki-67, HER-2/neu,
p53) were retrospectively determined in all cases with a sufficient
amount of tumour tissue left for analysis (Table 1). Multivariate
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Table 2 Summary measures for tumour-biological factors
Factor uPA PAI-1 S-phase Ki-67 p53 HER-2/neu Cathepsin D
(units) (ng mg21 (ng mg21 (%) (%) (%) (%) (pmol mg21
protein) protein) protein)
Minimum 0.07 0.06 1.08 0 0 0 10.6
1st quartile 0.86 4.11 3.27 1 0 0 25.67
Median 1.79 7.53 5.68 10 0 0 41.06
3rd quartile 3.67 13.19 9.53 20 0 10 66.67
Maximum 15.17 77.07 32.75 90 70 90 186.13
0123456789 1 0
Time (y ears)
PAI-1 lo w (n = 99)
11 relapses
PAI-1 high ( n = 26)
12 relapses
P < 0.001
1.0
0.8
0.6
0.4
0.2
0
01 2 34 56 7 891 0
Time (y ears)
1.0
0.8
0.6
0.4
0.2
0
Cathepsin D lo w (n = 60)
5 relapses
Cathepsin D high ( n = 61)
17 relapses
P = 0.004
012 34567891 0
Time (y ears)
1.0
0.8
0.6
0.4
0.2
0
SPF lo w (n = 55)
6 relapses
SPF high ( n = 46)
13 relapses
P = 0.023
Figure 1 PAI-1
Figure 2 Cathepsin D Figure 4 S-phase fraction (SPF)
Figures 1–4 Tumour-biological factors and their impact on disease-free survival (DFS) in node-negative breast cancer patients without adjuvant systemic
therapy
012 34 567891 0
Time (y ears)
1.0
0.8
0.6
0.4
0.2
0
uPA low ( n = 83)
10 relapses
uPA high ( n = 42)
13 relapses
P = 0.008
Figure 3 uPAanalyses were performed including those 96 patients for whom all
factors were available. Tumour-biological as well as traditional
factors were then related to patient outcome with a median follow-
up period of 76 months. To give an indication of the statistical
distributions of the tumour-biological factors, we report the
median and quartiles in Table 2.
The following cut-off values were optimized using log-rank
statistics and assigned for uPA (3 ng mg21 protein), PAI-1
(14 ng mg21 protein), total S-phase fraction (6%), Ki-67 (25%),
p53 (negative vs positive), HER-2/neu (2.5%; i.e. negative vs
positive), and cathepsin D (41 pmol mg21 protein) (Harbeck et al,
1998). Ploidy was coded as a binary variable into diploid (diploid
and near diploid) and aneuploid (an-, multi-, tetraploid) (Dettmar
et al, 1997).
Associations and correlations
The following associations between tumour-biological and tradi-
tional factors were significant (P , 0.05): uPA: grading only;
PAI-1: grading, hormone receptors, tumour size; p53: grading,
hormone receptors; Ki-67: grading only; S-phase: hormone recep-
tors, tumour size; ploidy: age only. Correlation co-efficients
between tumour-biological factors were assessed, and no strong
correlation (r . 0.50) between any of these factors was observed.
The following correlation co-efficients were significant: PAI-1 and
uPA (r 5 0.325); cathepsin D and uPA (r 5 0.272); cathepsin D
and PAI-1 (r 5 0.228); Ki-67 (MIB1) and p53 (r 5 0.314); S-
phase and uPA (r 5 0.321); S-phase and PAI-1 (r 5 0.218). As for
the two proliferation markers analysed, a significant correlation
was only seen between Ki-67 (MIB1) and aneuploid SPF
(P 5 0.011, r 5 0.383). Ploidy was significantly associated with
S-phase.
Univariate and multivariate analyses
In univariate analysis, PAI-1 (P , 0.001), cathepsin D (P 5
0.004), uPA (P 5 0.008) and SPF (P 5 0.023) are significantly
associated with disease-free survival (DFS) (Figures 1–4).
Adjusting the P-values according to Hilsenbeck and Clark (1996)
yields PAI-1 (P , 0.001), cathepsin D (P 5 0.08), uPA (P 5 0.16)
and SPF (P 5 0.32); quantitative analysis without dichotomization
yields PAI-1 (P , 0.001), cathepsin D (P 5 0.065), uPA (P 5
0.007) and SPF (P 5 0.055). Tumour size, steroid hormone
receptor status, grading, p53, HER-2/neu and Ki-67 (MIB1) have
no significant prognostic impact on DFS in our group of patients
after a median follow-up of more than 6 years. In multivariate
analysis, only PAI-1 (P , 0.001, relative risk (RR) 6.2; 95% CI
2.3–16.4) is of independent statistical significance for DFS.
A CART analysis for DFS was performed including all tradi-
tional and tumour-biological factors (Figure 5). It shows PAI-1 to
be the strongest factor for risk group selection (P , 0.001).
Patients with high PAI-1 levels (. 14 ng mg21 protein) in their
primary tumour belong to a high-risk group (n 5 26, 12 relapses)
for which no other prognostic factor was able to achieve a signifi-
cantly better sub-classification. In contrast, among patients with
low PAI-1 levels (≤ 14 ng mg21 protein), uPA turned out to be an
additional strong selection factor (P , 0.001), allowing patients to
be subdivided into groups with low PAI-1 and low or high uPA
antigen levels (≤/. 3 ng mg21 protein) in their primary tumours.
As a result, 56% of all patients belong to a low-risk group (n 5 70)
defined by low PAI-1 and low uPA levels encompassing only three
relapses (4%). Among the remaining 55 patients (44% of the total
125 patients) having high levels of PAI-1 or uPA, 20 relapses
(36%) are found within the follow-up period (Figures 5 and 6).
In order to compare our data within the time frame used in clin-
ical practice, we also looked at the 5-year relapse rates (Figure 7).
Patients with high PAI-1 levels in their tumours have the highest 5-
year relapse rate (47%). However, the combination of uPA and
PAI-1 gives the best definition of a low-risk group with a very low
3% relapse rate at 5 years. PAI-1, SPF and cathepsin D all have a
5-year relapse rate of 8% within their respective low-risk groups.
All other factors have an 11% or even higher 5-year relapse rate
within their low-risk set of patients. There was no qualitative
difference between 5-year relapse rates as estimated by
Kaplan–Meier analysis and relapse rates at the end of the follow-
up period (median 76 months). In conclusion, 20 of all 23 relapses
(87%) within the follow-up period were correctly classified by
elevated PAI-1 and/or uPA antigen levels determined in the
tumour tissue extracts at time of primary therapy.
For overall survival (OS), a similar picture emerged. PAI-1
proved to be a statistically significant independent prognostic
factor in both univariate and multivariate analysis (P , 0.001, RR
8.9; 95% CI 3.7–21.9). In addition, cathepsin D (P 5 0.010),
tumour size (P 5 0.035) and ploidy (P 5 0.049) were significant
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Figure 5 CART analysis for disease-free survival in node-negative breast
cancer patients without adjuvant systemic therapy, performed at a median
follow-up of 76 months
012 34 567891 0
Time (y ears)
1.0
0.8
0.6
0.4
0.2
0
uPA and PAI-1 lo w (n = 70)
3 relapses
uPA and / or P AI-1 high ( n = 55)
20 relapses
P < 0.001
Figure 6 The combination of uPA and PAI-1 and its impact on disease-free
survival (DFS) in node-negative breast cancer patients
uPA
n = 99; 11 relapses
n = 70, 3 relapses n = 29, 8 relapses n = 26, 12 relapses
96% 64%
Relapse-free Relapse-free
56% of
all patients
44% of
all patients
P < 0.001
P < 0.001
> 3 ng mg–1 protein
≤ 14 ng mg –1 protein > 14 ng mg –1 protein
≤ 3 ng mg–1 protein
PAI-1
n = 125;  23 relapsesin univariate but not in multivariate analysis. The adjusted P-
values (Hilsenbeck and Clark, 1996) for PAI-1 were P , 0.001
and for cathepsin P 5 0.18. All other tumour-biological and tradi-
tional factors had no significant prognostic impact on OS.
DISCUSSION
Of the eight tumour-biological factors investigated, only the three
factors describing the invasive and metastatic capacity of the
tumour (uPA, PAI-1, cathepsin D), and S-phase fraction (SPF), a
marker reflecting its proliferative potential, yielded statistically
significant prognostic information in node-negative breast cancer
patients. In contrast, the traditional prognostic factors (tumour
size, steroid hormone receptor status and grading) were of no value
to predict DFS or OS. After weighting the few significant factors
by multivariate analysis, only PAI-1 turned out to be of statistically
independent prognostic significance. This strong prognostic
impact of PAI-1 is also reflected by the low univariate P-values
even after adjustment for multiple testing as well as in quantitative
analysis.
In two earlier papers, after median follow-up periods of less
than 3 years, our group was the first to show that both PAI-1 and
uPA were significant prognostic factors in multivariate analysis for
DFS in both node-positive and node-negative breast cancer
patients (Jänicke et al, 1991, 1993). These results were subse-
quently confirmed by others (Grøhndahl-Hansen et al, 1993;
Bouchet et al, 1994; Foekens et al, 1994; Grøhndahl-Hansen et al,
1997a, 1997b) after median follow-up periods ranging from 4
(Foekens et al, 1994) to more than 8 years (Grøhndahl-Hansen et
al, 1993). All of these groups used cytosol preparations instead of
detergent extracts for determination of uPA and PAI-1 antigen
levels. Cytosols give comparable results for PAI-1 but may not
detect the full prognostic impact of uPA due to lower antigen
determination levels (Jänicke et al, 1994a). Statistical analyses
performed in our group of patients at different times of follow-up
suggested a variation of the prognostic strength of uPA and PAI-1
with time. The prognostic impact of uPA seems to be most
pronounced during the first 2 years after primary therapy, whereas
that of PAI-1 actually increased (Schmitt et al, 1997b). As shown
in the present publication, PAI-1 prevails as a strong prognostic
factor in node-negative breast cancer patients at a median follow-
up of more than 6 years. Moreover, this long-term follow-up
confirms our earlier findings that the combination of uPA and
PAI-1 is well suited to select a group of patients having a very low
risk of relapse (Jänicke et al, 1993, 1994b). In the low-risk group
(both uPA and PAI-1 low) after a median follow-up of more than 6
years, 96% of the patients remain relapse-free, in contrast to only
64% of patients in the high-risk group (either or both factors high).
Patients with either or both factors high have an 11-times higher
risk of recurrence than patients with both factors low. To our
knowledge, such a clear-cut risk-group separation has not been
demonstrated for any of the traditional factors, and indeed not for
any other tumour-biological factor. Independent validation using
additional patient data will be a very important next step.
Foekens et al (1994) presented similar data for a group of
primary breast cancer patients, including node-negative and node-
positive patients, and showed that patients with low levels of both
uPA and PAI-1 had a better prognosis than patients with either or
both factors high. Unfortunately, other groups who studied uPA
and PAI-1 in breast cancer have not looked at the prognostic
impact of the combination of the two factors. Definition of a low-
risk group having a very low risk of disease recurrence is,
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uPA / PAI-1 (*)
PAI-1 (£ vs > 14 ng mg
–1 protein)
SPF (£ vs > 6%)
Cathepsin D (£ vs > 41 pmol mg–1 protein)
uPA (£ vs > 3 ng mg
–1 protein)
Tumour size (£ vs > 2 cm)
Ploidy (diploid vs aneuploid)
Grading (G1/2 vs G3/4)
p53 (negative vs positive)
MIB1 (£ vs > 25%)
HER-2/neu (£ vs > 2.5%)
Steroid hormone receptor status
(negative vs positive)
0 1 02 03 04 05 0
5-year relapse rate (%)
Low-risk group
High-risk group
All patients Relative risk of recurrence (95% CI)
11.0 (3.2–37.4)
6.2 (2.7–14.6)
2.9 (1.1–7.6)
4.0 (1.9–10.8)
2.9 (1.3–6.6)
1.8 (0.8–4.2)
2.1 (0.8–5.5)
2.0 (0.8–4.8)
2.6 (0.8–9.0)
2.7 (1.1–6.6)
1.5 (0.6–3.7)
1.1 (0.4–3.0)
Figure 7 Five-year relapse rate in node-negative breast cancer patients without adjuvant systemic therapy was estimated by Kaplan–Meier analysis. Relative
risks of relapse and the 95% confidence intervals between the respective risk groups (high-risk vs low-risk group as determined by the respective prognostic
factor mentioned on the left) were calculated by univariate Cox analysis. *uPA/PAI-1: both factors low vs either or both factors highhowever, a prerequisite for any therapy recommendation consid-
ering prognostic factors. Based on our earlier results concerning
uPA, PAI-1 and breast cancer prognosis, a prospective multicentre
therapy trial was started in Germany in mid 1993 in which node-
negative patients with high uPA and/or PAI-1 antigen levels in
their primary tumours are randomized for adjuvant standard
CMF chemotherapy or observation only (Jänicke et al, 1994b).
This trial addresses two main issues: (1) Can the strong prognostic
impact of uPA and PAI-1 be confirmed in a prospective multi-
centre study and (2) do uPA and/or PAI-1 have a predictive value
with regard to administering CMF chemotherapy? At present,
about 650 patients are enrolled in this trial. We want to stress that
up to now no contradictory data regarding the prognostic impact of
uPA and PAI-1 in primary breast cancer have been reported in the
literature.
Over the last few years, data from basic research have accumu-
lated that may help to explain the clinical finding that not only
high levels of the protease uPA, but also high levels of its inhibitor
PAI-1, in the primary tumour tissue indicate poor patient outcome.
Whereas uPA facilitates metastasis by degradation of extracellular
matrix (Danø et al, 1985; Schmitt et al, 1997a), PAI-1 may play
another important role in tumour biology apart from being an
inhibitor of uPA. After interaction of PAI-1 with uPA already
complexed with the uPA receptor (uPAR), this ternary complex is
internalized into the cell, thereby initiating signal transduction and
cell proliferation. Moreover, PAI-1 acts as an inhibitor of cell
adhesion by interfering with attachment of the tumour cell to the
extracellular matrix component vitronectin (Stefansson et al,
1996; Wei et al, 1996). Interestingly, binding of uPA to PAI-1 may
reverse this process and support cell adhesion and migration
(Lauffenburger, 1996).
In addition to uPA and PAI-1, the protease cathepsin D also has a
significant prognostic impact on DFS and OS in our group of
patients as assessed by univariate analysis. This is quite consistent
with our earlier data (Jänicke et al, 1993). Foekens et al (1994) also
reported a prognostic impact of cathepsin D on DFS which did not
persist, however, in the presence of uPA and PAI-1 in multivariate
analysis. Spyratos et al (1992) also found uPA to be significant in
both univariate and multivariate analysis, whereas cathepsin D just
failed significance. Unfortunately, as shown in many investiga-
tions, methodological differences and heterogeneous patient collec-
tives have rendered the data regarding the prognostic impact of
cathepsin D quite controversial (Ravdin, 1993).
SPF, a proliferation marker, also showed a significant prognostic
impact in our set of node-negative patients after a median follow-
up of 76 months. This confirms earlier observations, where we
found after a median follow-up of 37.5 months that, even though
both SPF and Ki-67 were significant prognostic factors for DFS in
node-negative breast cancer patients, only SPF remained signifi-
cant in multivariate analysis (Dettmar et al, 1997). In the present
study, in a homogeneous group of node-negative patients who did
not receive any adjuvant systemic therapy at a considerably longer
median follow-up period of more than 6 years, Ki-67 was not able
to keep its prognostic significance. Other researchers who
compared SPF and Ki-67 also found SPF to give better prognostic
information, because Ki-67 either lost its univariate significance in
multivariate analysis (Gasparini et al, 1994) or was the weaker
factor in multivariate analysis (Brown et al, 1996). Wenger et al
(1993) published on a large data set and showed that SPF in breast
cancer has a significant prognostic impact on DFS in node-negative
patients (n 5 9736). There is a general agreement in the literature
that proliferation markers, and in particular SPF, provide valuable
information in breast cancer prognosis (Clark, 1996). Their clinical
usefulness could be greatly enhanced if methodological standard-
ization were performed. There are very few reports comparing
proliferation markers with other tumour-biological markers, in
particular with invasion markers. In our study, a statistically inde-
pendent prognostic impact of the proliferation marker SPF could
not be demonstrated when the invasion and metastasis markers uPA
and PAI-1 were included in the analysis. This may be partly due to
the fact that there are significant correlations between uPA/PAI-1
and SPF – a clinical finding that corresponds well with experi-
mental evidence suggesting that cell proliferation is stimulated
after internalization of the uPA/PAI-1/uPA-R complex.
Ploidy was not a statistically significant factor for DFS and only
of borderline significance for OS. Although there is considerable
(yet controversial) data concerning the importance of ploidy in
breast cancer prognosis (McGuire and Clark, 1992), most authors
seem to agree on the fact that, if at all, ploidy is of low prognostic
power.
HER-2/neu and p53 did not contribute any significant prog-
nostic information in our set of node-negative patients. We note
that the literature regarding these two factors is still very much in
disagreement concerning their prognostic value (Clark, 1996). For
HER-2/neu, both detection of protein overexpression by immuno-
histochemistry as well as immunoblotting for detection of gene
amplification have been used in the past to study its prognostic
impact. A new approach, detection of HER2/neu gene amplifica-
tion by fluorescence in situ hybridization (FISH), has recently
been introduced to identify high-risk node-negative breast cancer
patients (Press et al, 1997) and seems to be superior to the
immunohistochemical approach. As for p53, it is still under
discussion whether mutant p53 and/or wild-type p53 are associ-
ated with the malignant phenotype.
In conclusion, substantial evidence has accumulated that the
invasion and metastasis markers uPA and PAI-1, as well as the
proliferation marker SPF, are able to generate clinically relevant
prognostic information in node-negative breast cancer patients.
Serious efforts towards international standardization, particularly
for uPA and PAI-1 determination, have been recently undertaken
(Benraad et al, 1996). Similar quality control studies have been
introduced for flow cytometric DNA analysis (D’hautcourt et al,
1996), and international guidelines for DNA flow cytometry were
proposed by the International Society for Analytical Cytology
(ISAC) (Hiddemann et al, 1984). Reliable and standardizable SPF
calculation has been made possible by modern evaluation software
in both paraffin and fresh tumour tissue (Bagwell et al, 1991).
Consequently, uPA, PAI-1 and SPF seem to be the tumour-biolog-
ical prognostic markers that are most suited for transfer into clin-
ical practice (Graeff et al, 1997). Recommendations of the EORTC
Receptor and Biomarker Study Group to include these factors into
the routine panel for breast cancer patient assessment were put
forward in 1995 (Blankenstein, 1997). Additional studies
comparing several of these tumour-biological prognostic factors in
homogeneous patient cohorts with sufficient follow-up periods are
needed. Together with preliminary results of the German prospec-
tive therapy trial, they will help not only to further determine the
prognostic impact of uPA and PAI-1 (and facultative tumour-
biological factors) in node-negative breast cancer, but also to eval-
uate their predictive value with regard to therapy response.
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